SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

EVAX

Evaxion
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

Traders should prepare for potential volatility following the March 5 earnings release. Monitor the upcoming financial results for revenue, cash runway, and R&D spend, which will be critical for assessing the company's development trajectory.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.17
T+0 close · Mar 2, 2026 · via day close
Latest settled
+29.65%
T+60 · $4.11
Vs SPY
+20.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $3.17entry
  2. T+1 · 9mo ago −1.58%α −0.66% · $3.12
  3. T+5 · 8mo ago −2.84%α −1.63% · $3.08
  4. T+20 · 8mo ago +18.93%α +26.87% · $3.77
  5. T+60 · 6mo ago +29.65%α +20.33% · $4.11
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced it will release its full-year 2025 financial results and provide a business update on March 5, 2026, followed by a conference call. The press release contains no financial data or material operational updates, only logistical details for the upcoming earnings event.

Key Facts

  • Evaxion will report full-year 2025 financial results on March 5, 2026, before Nasdaq opens.
  • Management will host a conference call and webcast the same day at 08:30 EST / 14:30 CET.
  • No financial results, guidance, or material business updates were disclosed in this announcement.
  • The release includes forward-looking statements and risk disclosures typical of public biotech companies.

Financial Impact

No financial impact from this announcement alone, no data disclosed.

Risk Factors

  • Low liquidity and high volatility risk due to small market cap ($26M).
  • Forward-looking statements suggest significant risks around funding, clinical development, and regulatory pathways.
  • No financials or updates provided, actual results could surprise to the upside or downside.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247291

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026